Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XH9B
|
|||
| Former ID |
DIB000311
|
|||
| Drug Name |
Tabimorelin
|
|||
| Synonyms |
NN-703; NNC-26-0703; Tabimorelin; N-[5-Amino-5-methyl-2(E)-hexenoyl]-N-methyl-3-(2-naphthyl)-D-alanyl-N-methyl-D-phenylalanine methylamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Growth hormone deficiency [ICD-11: 5A61.3] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H40N4O3
|
|||
| Canonical SMILES |
CC(C)(CC=CC(=O)N(C)C(CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)C(CC3=CC=CC=C3)C(=O)NC)N
|
|||
| InChI |
1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
|
|||
| InChIKey |
WURGZWOTGMLDJP-ZCYANPAGSA-N
|
|||
| CAS Number |
CAS 193079-69-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth hormone secretagogue receptor 1 (GHSR) | Target Info | Modulator | [1] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.